Stock / equity
DBTX Decibel Therapeutics, Inc.
- Company
- Decibel Therapeutics, Inc.
- Security
- Equity
- Insiders on record
- 1
- Latest trade on record
- February 17, 2021
DBTX (Decibel Therapeutics, Inc.) has 0 disclosed insider transactions from 0 insiders in the last 12 months (0 open-market buys, 0 sales, about $0 at reported prices) and 0 congressional trades from 0 members of Congress. The most recent disclosure was filed February 19, 2021.
Share price
Price and chart by TradingView for Decibel Therapeutics, Inc.. US share prices here are delayed, not real-time. The trade records on this page come from government filings, not from this chart.
Insiders trading DBTX
Everyone who filed a Form 4 for this ticker, by number of rows on record. "Bought" and "sold" count open-market purchases (code P) and sales only; awards, option exercises and shares withheld for tax are in the row count but not in those two columns.
| Insider | Role | Rows | Bought | Sold | Value bought | Value sold | Latest |
|---|---|---|---|---|---|---|---|
| GLAXOSMITHKLINE PLC | Insider | 7 | 1 | 0 | $2.7M | — | February 17, 2021 |
What kind of transactions these are 2 Form 4 codes
| Code | Meaning | Rows | Shares | Value at reported prices |
|---|---|---|---|---|
| C | Conversion of a derivative | 6 | 13,016,132 | — |
| P | Open-market purchase | 1 | 150,000 | $2.7M |
What each code means: Form 4 transaction codes.
Insider transactions
| Filer | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| GLAXOSMITHKLINE PLC | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 1,737,619 | — | — | indirectderivative | Form 4 ↗ | |
| GLAXOSMITHKLINE PLC | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 3,125,000 | — | — | indirectderivative | Form 4 ↗ | |
| GLAXOSMITHKLINE PLC | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 7,119,850 | — | — | indirectderivative | Form 4 ↗ | |
| GLAXOSMITHKLINE PLC | Buy P | February 17, 2021 | February 19, 2021 | 2d | 150,000 | $18 | $2.7M | indirect | Form 4 ↗ | |
| GLAXOSMITHKLINE PLC | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 327,852 | — | — | indirect | Form 4 ↗ | |
| GLAXOSMITHKLINE PLC | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 247,324 | — | — | indirect | Form 4 ↗ | |
| GLAXOSMITHKLINE PLC | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 458,487 | — | — | indirect | Form 4 ↗ |
Congressional trades
No member of Congress has disclosed a trade in this ticker in the filings we have parsed.
Related stocks
Tickers traded by the same people who traded DBTX, by number of filers in common. It shows overlap in public filings and nothing else.
- WVE Wave Life Sciences, Inc. 1 filer in common
- BCYC BICYCLE THERAPEUTICS PLC 1 filer in common
- CVRX CVRx, Inc. 1 filer in common
- INVA Innoviva, Inc. 1 filer in common
- LYEL Lyell Immunopharma, Inc. 1 filer in common
- GNCA GENOCEA BIOSCIENCES, INC. 1 filer in common
- TBPH Theravance Biopharma, Inc. 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 7 | February 19, 2021 | February 19, 2021 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insider rows are Form 4 filings for this issuer from SEC EDGAR; congressional rows are periodic transaction reports parsed from the House Clerk and the Senate eFD. Values use the reported price for Form 4 and the disclosed range for Congress. See methodology and corrections.
Not investment advice. Disclosures are shown as filed and may lag the trade or be amended. No recommendation is made or implied.